Form 8-K - Current report:
SEC Accession No. 0001390478-22-000021
Filing Date
2022-08-11
Accepted
2022-08-11 16:14:53
Documents
13
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20220811.htm   iXBRL 8-K 41404
2 EX-99.1 sls-202208118xkexhibit991.htm EX-99.1 101911
  Complete submission text file 0001390478-22-000021.txt   296752

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20220811.xsd EX-101.SCH 1929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20220811_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20220811_pre.xml EX-101.PRE 13065
7 EXTRACTED XBRL INSTANCE DOCUMENT sls-20220811_htm.xml XML 11895
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 221156039
SIC: 2834 Pharmaceutical Preparations